Selected article for: "mortality rate and viral infection"
Author: Khawaja, Fareed; Chemaly, Roy F.
Title: Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies
  • Document date: 2019_7_23
    • ID: 4fx18mlj_35
    Snippet: RSV is a common respiratory viral infection in adult HM patients and HCT recipients. Its incidence is affected by its seasonality and geography and the diagnostic method used. The mortality rate associated with RSV can be high in severely immunocompromised patients with LRTI. The use of an ISI is helpful to stratify HCT recipients into risk categories; a similar scoring system is needed for HM patients. Ribavirin, with or without IVIG, may mitiga.....
    Document: RSV is a common respiratory viral infection in adult HM patients and HCT recipients. Its incidence is affected by its seasonality and geography and the diagnostic method used. The mortality rate associated with RSV can be high in severely immunocompromised patients with LRTI. The use of an ISI is helpful to stratify HCT recipients into risk categories; a similar scoring system is needed for HM patients. Ribavirin, with or without IVIG, may mitigate the impact of RSV infections in this population of patients. The further development of new antiviral agents or other treatment modalities is of the utmost importance to have a greater impact on rates of progression to LTRI and mortality in adult HM patients and HCT recipients.

    Search related documents:
    Co phrase search for related documents
    • antiviral agent and new antiviral agent: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • diagnostic method and great impact: 1
    • diagnostic method and mortality rate: 1, 2, 3
    • great impact and mortality rate: 1, 2, 3, 4, 5, 6, 7
    • great impact and progression rate: 1
    • HCT recipient and mortality rate: 1
    • HM patient and mortality rate: 1
    • mortality rate and patient population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mortality rate and progression rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • patient population and progression rate: 1, 2